IN the summer of 2019, a mother in Nashville, Tennessee in the United States, with a seemingly incurable genetic disorder finally found an end to her suffering by editing her genome.
Victoria Grays recovery from sickle cell disease, which had caused her painful seizures, came in a year of breakthroughs in one of the hottest areas of medical research gene therapy.
I have hoped for a cure since I was about 11, the 34-year-old said.
Since I received the new cells, I have been able to enjoy more time with my family without worrying about pain or an out-of-the-blue emergency.
Over several weeks, Grays blood was drawn so that doctors could get to the cause of her illness stem cells from her bone marrow that were making deformed red blood cells.
The stem cells were sent to a Scottish laboratory, where their DNA was modified using Crispr/Cas9 pronounced Crisper a new tool informally known as a molecular scissors.
The genetically-edited cells were transfused back into Grays veins and bone marrow. A month later, she was producing normal blood cells.
Medics warn that caution is necessary, but theoretically, she has been cured.
This is one patient. This is early results. We need to see how it works out in other patients, said her doctor, Haydar Frangoul, at the Sarah Cannon Research Institute in Nashville.
But these results are really exciting.
In Germany, a 19-year-old woman was treated with a similar method for a different blood disease beta thalassemia.
She had previously needed 16 blood transfusions per year. Nine months later, she is completely free of that burden.
For decades, the DNA of living organisms such as corn and salmon has been modified. But Crispr, invented in 2012, made gene editing more widely accessible.
It is much simpler than preceding technology, cheaper and easy to use in small labs.
The technique has given new impetus to the perennial debate over the wisdom of humanity manipulating life itself.
Its all developing very quickly, said French geneticist Emmanuelle Charpentier, one of Crisprs inventors and the co-founder of Crispr Therapeutics, the biotech company conducting the clinical trials involving Gray and the German patient.
Crispr was the latest breakthrough in a year of great strides in gene therapy, a medical adventure that started three decades ago, when the first TV telethons were raising money for children with muscular dystrophy.
Scientists practising the technique insert a normal gene into cells containing a defective gene.
It does the work the original could not, such as making normal red blood cells in Grays case or making tumour-killing super white blood cells for a cancer patient.
Crispr goes even further: instead of adding a gene, the tool edits the genome itself.
After decades of research and clinical trials on a genetic fix to genetic disorders, 2019 saw a historic milestone: approval to bring to market the first gene therapies for a neuromuscular disease in the US and a blood disease in the European Union.
They join several other gene therapies bringing the total to eight approved in recent years to treat certain cancers and an inherited blindness.
Serge Braun, the scientific director of the French Muscular Dystrophy Association, sees 2019 as a turning point that will lead to a medical revolution.
Twenty-five, 30 years, thats the time it had to take, he said. It took a generation for gene therapy to become a reality. Now, its only going to go faster.
Just outside Washington, at the US National Institutes of Health (NIH), researchers are also celebrating a breakthrough period.
We have hit an inflection point, said US NIHs associate director for science policy Carrie Wolinetz.
These therapies are exorbitantly expensive, however, costing up to US$2 million (RM8.18 million) meaning patients face grueling negotiations with their insurance companies.
They also involve a complex regimen of procedures that are only available in wealthy countries.
Gray spent months in hospital getting blood drawn, undergoing chemotherapy, having edited stem cells reintroduced via transfusion and fighting a general infection.
You cannot do this in a community hospital close to home, said her doctor.
However, the number of approved gene therapies will increase to about 40 by 2022, according to Massachusetts Institute of Technology (MIT) researchers.
They will mostly target cancers and diseases that affect muscles, the eyes and the nervous system.
In this Oct 10, 2018, photo, He speaks during an interview at his laboratory in Shenzhen, China. The scientist was recently sentenced to three years in prison for practicing medicine illegally and fined 3 million yuan (RM1.76 million). AP
Another problem with Crispr is that its relative simplicity has triggered the imaginations of rogue practitioners who dont necessarily share the medical ethics of Western medicine.
In 2018 in China, scientist He Jiankui triggered an international scandal and his excommunication from the scientific community when he used Crispr to create what he called the first gene-edited humans.
The biophysicist said he had altered the DNA (deoxyribonucleic acid) of human embryos that became twin girls Lulu and Nana.
His goal was to create a mutation that would prevent the girls from contracting HIV (human immunodeficiency virus), even though there was no specific reason to put them through the process.
That technology is not safe, said Kiran Musunuru, a genetics professor at the University of Pennsylvania, explaining that the Crispr scissors often cut next to the targeted gene, causing unexpected mutations.
Its very easy to do if you dont care about the consequences, he added.
Despite the ethical pitfalls, restraint seems mainly to have prevailed so far.
The community is keeping a close eye on Russia, where biologist Denis Rebrikov has said he wants to use Crispr to help deaf parents have children without the disability.
There is also the temptation to genetically edit entire animal species, e.g. malaria-causing mosquitoes in Burkina Faso or mice hosting ticks that carry Lyme disease in the US.
The researchers in charge of those projects are advancing carefully however, fully aware of the unpredictability of chain reactions on the ecosystem.
Charpentier doesnt believe in the more dystopian scenarios predicted for gene therapy, including American biohackers injecting themselves with Crispr technology bought online.
Not everyone is a biologist or scientist, she said.
And the possibility of military hijacking to create soldier-killing viruses or bacteria that would ravage enemies crops?
Charpentier thinks that technology generally tends to be used for the better.
Im a bacteriologist -- weve been talking about bioterrorism for years, she said. Nothing has ever happened. AFP Relaxnews
- Global Stem Cell Market Poised for Strong Growth as Global Regenerative Medicine Market Poised to Reach US$45 billion by 2025 - P&T Community - February 28th, 2020
- Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update - BioSpace - February 28th, 2020
- Creative Medical Technology Holdings Inc (OTCMKTS: CELZD) Gets the Extra D - MicroCap Daily - February 28th, 2020
- If medications fail, surgery option for treating infectious retinitis - Ophthalmology Times - February 28th, 2020
- BTK Inhibitors Offer Improved Response Over Chemotherapy in Mantle Cell Lymphoma - Curetoday.com - February 28th, 2020
- Aspire Regenerative Medical Director Featured on New Podcast - PR Web - February 28th, 2020
- Global Regenerative Medicine Market Briefing 2020, Trends, Applications, Types, Research, Forecast To 2025 - Bandera County Courier - February 28th, 2020
- New study identifies trigger that turns dormant cancer stem cells into active ones - Yahoo Finance - February 27th, 2020
- Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update - Yahoo Finance - February 27th, 2020
- On the Road to 3-D Printed Organs - The Scientist - February 27th, 2020
- Researchers have found a probable cure for diabetes and we need to thank diabetic lab mice for it - International Business Times, Singapore Edition - February 27th, 2020
- Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML with off-the-shelf NK cells from universal donors -... - February 27th, 2020
- Immune-Based Therapies Emerge in Mantle Cell Lymphoma - Curetoday.com - February 24th, 2020
- Texas A&M Researcher Named To National List Of Inspiring Black Scientists - Texas A&M University - February 24th, 2020
- Locking in and preserving your healthy stem cells has never been easier and more accessible as Acorn Biolabs partners with Coverdale Clinics. - Canada... - February 22nd, 2020
- Chinese Scientist Unite Together to Tackle With COVID-19 - Benzinga - February 22nd, 2020
- Army spouse dances her way through chemotherapy - We Are The Mighty - February 22nd, 2020
- The Winnipeg Foundation Innovation Fund supports cutting-edge research - UM Today - February 22nd, 2020
- Locking in and preserving your healthy stem cells has never been easier and more accessible as Acorn Biolabs partners with Coverdale Clinics. - Yahoo... - February 20th, 2020
- Missouri S&T researchers create organ tissue with bioactive glass, stem cells and 3D printer - The Rolla Daily News - February 20th, 2020
- Regenerative Medicine Market trends, leaders, segment analysis and forecast to 2030 described in a new market report - WhaTech Technology and Markets... - February 16th, 2020
- 5 Aesthetic Clinics To Know In The Klang Valley & Their Signature Treatments - Malaysia Tatler - February 14th, 2020
- Tech Ventures kicks off series dedicated to supporting female inventors and entrepreneurs at Johns Hopkins - The Hub at Johns Hopkins - February 14th, 2020
- BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update - GlobeNewswire - February 11th, 2020
- CD229 CAR T-cell therapy treated tumours had lasting response mice - Drug Target Review - February 11th, 2020
- BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update - BioSpace - February 11th, 2020
- Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma - Cancer Network - February 9th, 2020
- Physical forces at the interface with biology and chemistry - PLoS Blogs - February 9th, 2020
- Scientists create 'Chemical gardens' that can be used as bone substitute materials - University of Birmingham - February 7th, 2020
- Lab-grown heart cells implanted into human patient for the first time - New Atlas - January 29th, 2020
- Engineer the future of human health with a PhD in biomedical engineering - Study International News - January 29th, 2020
- GIOSTAR Announces Medical Breakthrough in Biotechnology and Lifesciences To Manufacture Abundant, Safe Red Blood Cells From Stem Cells - Benzinga - January 29th, 2020
- Study suggests Parkinson's present from birth and may be preventable - New Atlas - January 29th, 2020
- Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit - Yahoo Finance - January 22nd, 2020
- The Brave New World of Organoids - North Forty News - January 22nd, 2020
- The Tiny Brain Cells That Connect Our Mental and Physical Health - WIRED - January 22nd, 2020
- Organicell Regenerative Medicine Inc. Provides Update On Operations and Financial Reporting Status - GlobeNewswire - January 22nd, 2020
- Novel mutations in stem cells of young donors can be passed to recipients - BioNews - January 21st, 2020
- Gains in Stem Cell Transplant Mortality Over Last 25 Years - MedPage Today - January 21st, 2020
- Biomedical Applications of Zeolitic Nanoparticles, with an Emphasis on | IJN - Dove Medical Press - January 21st, 2020
- Cell therapy trialed in mice offers diabetes treatment hope - SelectScience - January 21st, 2020
- Scientists Image Heart RNA Structure for the First Time - Diagnostic and Interventional Cardiology - January 21st, 2020
- CAR T-Cell Therapy and Beyond: Off-the-Shelf Therapies Among Innovations at ASH 2019 - AJMC.com Managed Markets Network - January 21st, 2020
- Stem Cell Assay Market to Expand at a Healthy CAGR of XX% Between and 2017 2025 Dagoretti News - Dagoretti News - January 21st, 2020
- Introducing Generate Life Sciences - A First-Of-Its-Kind Company Focused On Helping Grow And Protect Healthy Families - Yahoo Finance - January 19th, 2020
- Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer - Yahoo Finance - January 19th, 2020
- Regenerative Medicine Market 2026: Product Approvals and Growing Pipeline of Regenerative Medicine P - PharmiWeb.com - January 18th, 2020
- Mutations in donors' stem cells may cause problems for cancer patients - Washington University School of Medicine in St. Louis - January 18th, 2020
- Global Cell Expansion Market by Type, Share Analysis, Top Players Eyeing to Penetrate Into Emerging Nations with Untapped Opportunities 2024 ... - January 18th, 2020
- Introducing Generate Life Sciences - A First-Of-Its-Kind Company Focused On Helping Grow And Protect Healthy Families - PRNewswire - January 18th, 2020
- Stem Cell and Regenerative Medicine Action Awards to be Presented at World Stem Cell Summit on January 23 at the Hyatt Regency Miami - GlobeNewswire - January 12th, 2020
- SNACS: The FAANG Of The Roaring 20s - Yahoo Finance - January 12th, 2020
- 20 Technology Metatrends That Will Define the Next Decade - Singularity Hub - January 12th, 2020
- LANL Scientists And International Partners Create 3-D Image Of Heart RNA Structure For First Time - My Blog - Los Alamos Daily Post - January 12th, 2020
- MicroCures Awarded $1.5M SBIR Grant To Support Development of Novel Therapeutic Platform for Accelerated Tissue Repair - BioSpace - January 8th, 2020
- 2020 Exosome Technologies Market Top Companies Analysis Including Capricor Therapeutics Inc, Evox Therapeutics Ltd, ReNeuron Group Plc, Stem Cell... - January 8th, 2020
- BrainStorm Cell Therapeutics Wins 2020 'Buzz of BIO' Award for ALS Investigational Therapy - ALS News Today - January 3rd, 2020
- Cell and Advanced Therapies Supply Chain Management Industry Report, 2019-2030 - GlobeNewswire - January 3rd, 2020
- miRNAs: A Promising Target in the Chemoresistance of Bladder Cancer | OTT - Dove Medical Press - January 3rd, 2020
- China confirms third birth of gene-edited baby; scientists involved get prison terms - WRAL Tech Wire - January 3rd, 2020
- Gene Therapies Make it to Clinical Trials - Discover Magazine - December 31st, 2019
- What is HLH, and what role did it play in the death of a healthy 34-year-old ESPN reporter? - FirstCoastNews.com WTLV-WJXX - December 29th, 2019
- 2019: The year gene therapy came of age - INQUIRER.net - December 29th, 2019
- Stem Cells Market is Expected to Expand at an Impressive Rate by 2023 - News Cast Report - December 29th, 2019
- ESPN reporter diagnosed with pneumonia, HLH. What is HLH? - Crossroads Today - December 27th, 2019
- 2019: the year gene therapy came of age - Times of India - December 27th, 2019
- This Is How Human Head Transplants Could Be Achieved, According To A Neurosurgeon - IFLScience - December 25th, 2019
- Taiwan Healthcare+ Expo 2019: A 360 exposure to MedTech and Therapeutic world - BSA bureau - December 22nd, 2019
- Lawmakers Present Mother & Daughter With the Signed Bill They Inspired - River Journal Staff - December 22nd, 2019
- Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors - GlobeNewswire - December 22nd, 2019
- Association Between Change in Circulating Progenitor Cells During Exercise Stress and Risk of Adverse Cardiovascular Events in Patients With Coronary... - December 20th, 2019
- The Most Significant Cancer Research Advances of the 2010s - Dana-Farber Cancer Institute - December 20th, 2019
- Metabolic dysregulation: origins of neurodegenerative disease - Health Europa - December 20th, 2019
- Inside the US-Iran prisoner swap, and what comes next - Al-Monitor - December 20th, 2019
- Global Stem Cell Therapy Market to Surpass US$ 40.3 Billion by 2027 Coherent Market Insights - Business Wire - December 18th, 2019
- The 3D cell culture market is projected to reach USD 1,846 million by 2024 from USD 892 million in 2019, at a CAGR of 15.7% - PRNewswire - December 18th, 2019
- Orthopaedic Surgeon, Dr. Jeffrey Carlson, first in Central and Eastern Virginia to implant the M6-C Artificial Cervical Disc - BioSpace - December 18th, 2019
- Gene Therapy for Sickle-Cell Anemia Looks Promisingbut It's Riddled With Controversy - Singularity Hub - December 18th, 2019
- Orbiting Organoids: Research in Space to Unveil New Neurodegeneration Insight - Xconomy - December 18th, 2019
- Dr. Jack Zamora Partners with the Exclusive Haute Beauty Network - PR Web - December 18th, 2019